Key result
Interrupting rivaroxaban after pericardial window for DOAC-associated hemopericardium linked to recurrent PE.
Why the study?
There are no guidelines on when to restart anticoagulation after pericardial window for DOAC-associated hemopericardium.
Case Report (n=1)
This case highlights the clinical dilemma and lack of guidelines regarding when to restart anticoagulation after a pericardial window for DOAC-associated hemopericardium.
Answers are grounded in this paper and cite their sources.
Holding anticoagulation after pericardial window for hemopericardium risks recurrent PE; leaves open optimal DOAC management in high-risk patients.
We present a female patient with a history of systolic heart failure with an ejection fraction of 25-30%, and unprovoked pulmonary embolism on extended anticoagulation therapy with rivaroxaban who underwent a pericardial window for cardiac tamponade due to hemopericardium in the setting of direct oral anticoagulant (DOAC). The rivaroxaban was held following the pericardial window, and she experienced another episode of pulmonary embolism before the rivaroxaban could be restarted. Currently, there are no guidelines on when to restart anticoagulation postpericardial window for DOAC-associated hemopericardium. Studies are needed to help solve this dilemma.
No takes yet. Share an insight, caveat, or question.
Kesiena et al. (2023) conducted a case report in Hemopericardium and cardiac tamponade on DOAC therapy (n=1). Interruption of rivaroxaban was evaluated on Recurrent pulmonary embolism. Interruption of rivaroxaban following a pericardial window for DOAC-associated hemopericardium resulted in a recurrent episode of pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: